The Arctic contains an estimated 30 percent of the globe’s untapped gas reserves and 13 percent of its untapped oil reserves
Less competition and shortages are pushing up drug prices
Anti-gun activists mistakenly believe they can win "a war for the culture." A year after Newtown, it's easier to buy firearms
Cell biologist Randy Schekman's lab will no longer submit papers to the big-name journals. Here's why
The Jones Act, an isolationist law passed in 1920, messes with oil shipments
You may not have heard of the low-budget shows produced by this stand-up comic turned media mogul, but they're the future of TV—and he's killing it
The chef-owner of America's most secretive restaurant finally talks
Northwestern's Kellogg School of Management reclaims the top stop after a two-year absence
The Santa Spy Cam app—which superimposes Santa, elves, and even reindeer on moving images of a given home—is an overnight hit with parents who face skeptical kids
Founder: Dr. Mark Pruzanski
VC Investment over the last four quarters: $25 million
Founded in 2002, the 25-employee biopharmaceutical company is in the process of developing therapeutic treatment of chronic fibrotic and metabolic diseases. Despite the downturn, the company raised significant funding this year. Sticking to a tight budget, Intercept expects to have enough cash resources to fund its operations until 2010.
Key to startup success: "Be persistent. Intercept was founded just before the last major downturn for biotech, which lasted through 2003 and venture capital completely dried up for new early-stage startups. [We] remained passionately dedicated to the company and persisted even though it took more than a year to secure financing."